Last reviewed · How we verify
NCT05474950: MINOCME
Minocycline Treatment for Cystoid Macular Edema
Phase 1, PHASE2 trial testing minocycline in Minocycline in 5 participants. Status unknown.
1 June 2024
Quick facts
| Lead sponsor | Sun Yat-sen University |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 5 |
| Start date | 1 January 2019 |
| Primary completion | 1 June 2024 |
| Estimated completion | 1 June 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- minocycline (MINOCYCLINE) — full drug profile →
Conditions studied
- Minocycline — all drugs for Minocycline →
- Cystoid Macular Edema — all drugs for Cystoid Macular Edema →
Sponsor
Sun Yat-sen University
Who can join
Adults 18 to 70, any sex, with Minocycline or Cystoid Macular Edema. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Cystoid macular edema (CME) is one of sight-threatening, immune-related ocular diseases. The efficacy of current treatments for CME (anti-VEGF, glucocorticoids and other agents) are limiting. Minocycline, acting as a broad-spectrum antibiotic, is among tetracycline family and recently, its immunomodulatory and anti-apoptosis function has been replied to several immune diseases and degenerative diseases. This study aims to explore the efficacy and safety of minocycline for CME.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05474950
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of minocycline
Trials testing the same drug.
- NCT06307288 — Efficacy and Safety of Tranilast Combined With Minocycline in the Treatment of Rosacea · Phase 4 · unknown
- NCT05958069 — The Efficacy and Safety of Minocycline in the Treatment of Drug-resistant Epilepsy in NORSE Patients · NA · unknown
- NCT05474729 — Minocycline for Chronic Autoimmune Uveitis · Phase 1, PHASE2 · recruiting
Other recruiting trials for Minocycline
Currently open trials in the same condition.
- NCT05512910 — Minocycline for Acute Ischemic Stroke Undergoing Endovascular Treatment Due to Basilar Artery Occlusion (MIST-B) · Phase 4 · active not recruiting
- NCT05474729 — Minocycline for Chronic Autoimmune Uveitis · Phase 1, PHASE2 · recruiting
Other Sun Yat-sen University trials
Trials by the same sponsor.
- NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
- NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
- NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
- NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
- NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05474950 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
- Last refreshed: 19 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05474950.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing